Annual cashflow statement for IN8bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -14.7 | -28.5 | -30 | -30.4 | -19.4 |
| Depreciation | |||||
| Non-Cash Items | 2.36 | 3.96 | 5.04 | 5.87 | 3.92 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1.84 | -0.17 | -0.204 | -1.41 | 1.04 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -13.5 | -24.1 | -23.3 | -24.1 | -12.7 |
| Capital Expenditures | -0.309 | -3.71 | -0.6 | -0.187 | 0 |
| Purchase of Fixed Assets | |||||
| Cash from Investing Activities | -0.309 | -3.71 | -0.6 | -0.187 | 0 |
| Financing Cash Flow Items | -2.69 | 0 | — | -0.089 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 33 | 8.99 | 27 | 14.2 | 28.6 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 19.1 | -18.8 | 3.1 | -10.2 | 15.9 |